HIV-1, Treatment-naïve
Conditions
Brief summary
Improved survival of people living with HIV has resulted in an increased occurrence of other comorbidities, such as cardiovascular, renal, bone and endocrine pathologies. The data that is currently available on cART-associated changes in bone mineral density, body composition and hormonal values is short-term and mainly derived from patients initiating cART in accordance with previous treatment guidelines. As current guidelines recommend earlier cART initiation and as PI-based regimens are becoming less frequently used, a favorable outcome on bone health, body composition measures and endocrine status might be expected. This study will therefore prospectively document alterations in bone mineral density, body composition and endocrine status in HIV-infected patients in whom, in the current treatment era, an INSTI-based cART regimen is initiated as a first line regimen.
Detailed description
Patients will be included at the initiation of cART. The follow up for this study is planned to fit within the routine follow up consultations and includes some extra experimental investigations, such as the medical body composition measurements, resting energy expenditure measurement, Achilles bone ultrasonometer and DXA scans. Standard blood and urine samples will be taken, including standard analyses and some extra analyses for the study. Physical activity will be monitored for 5 consecutive days using a bracelet device while patients will be asked to record their food intake using a standardized diet agenda. Total follow up time will be 144 weeks and includes 12 visits in total.
Interventions
RADIATIONDXA scan
total and hip and spine dual energy x-ray absorptiometry
OTHERAchilles bone US
OTHERMedical body composition measurements
Sponsors
Universitair Ziekenhuis Brussel
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Documented and confirmed HIV-1-infection * Aged 18 years or above * Naïve to anti-retroviral treatment, unless anti-retrovirals were taken in the context of occupational or non-occupational post-exposure prophylaxis or in the context of prevention of mother-to-child transmission * Willingness to sign the written informed consent
Exclusion criteria
* Pregnancy and breastfeeding * Patients receiving medical care through an 'emergency care package'
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of changes in BMD from baseline | 144 weeks of follow-up |
| Assessment of changes in trunk fat from baseline | 144 weeks of follow-up |
| Determination of the incidence of subclinical and clinical hypothyroidism | Within 144 weeks of follow-up |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between T-scores obtained by Achilles bone ultrasonometer (screening tool) and hip and spine DXA scan (gold standard) | 144 weeks of follow-up |
| Description of changes in body composition in relation to the resting energy expenditure | 144 weeks of follow-up |
| Correlations between changes in body composition and endocrine values | 144 weeks of follow-up |
| Correlation between changes in VAT and trunk fat and changes in waist circumference | 144 weeks of follow-up |
Countries
Belgium
Outcome results
None listed